Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
AssigneeHopital Sainte-Justine
InventorsErnest G. Seidman, Yves Theoret
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
Claims36
-25. (canceled)
A method for testing 6-thioguanine levels in a subject receiving azathioprine or 6-mercaptopurine, said method comprising:
- (a) receiving blood drawn from a subject who has been administered azathioprine or 6-mercaptopurine;
- (b) using a high performance liquid chromatography instrument to determine a level of 6-thioguanine present in said subject;
- and
- (c) indicating that a level of 6-thioguanine between about 230 pmol per 8×108 red blood cells and about 450 pmol per 8×108 red blood cells is optimal.
A method for testing 6-thioguanine levels in a subject receiving azathioprine or 6-mercaptopurine, said method comprising:
- (a) receiving blood drawn from a subject who has been administered azathioprine or 6-mercaptopurine;
- (b) using a high performance liquid chromatography instrument to determine a level of 6-thioguanine present in said subject;
- (c) indicating that a 6-thioguanine level of less than about 230 pmol per 8×108 red blood cells is associated with lower efficacy;
- and
- (d) indicating that a 6-thioguanine level of greater than about 450 pmol per 8×108 red blood cells is associated with toxicity.
A method for testing 6-thioguanine levels in a subject receiving azathioprine or 6-mercaptopurine, said method comprising:
- (a) receiving blood drawn from a subject who has been administered azathioprine or 6-mercaptopurine;
- (b) using a high performance liquid chromatography instrument to determine a level of 6-thioguanine present in said subject;
- (c) corresponding said determined level of 6-thioguanine to a red blood cell level;
- and
- (d) indicating that a level of 6-thioguanine between about 230 pmol per 8×108 red blood cells and about 450 pmol per 8×108 red blood cells is optimal.
A method for testing 6-thioguanine levels in a subject receiving azathioprine or 6-mercaptopurine, said method comprising:
- (a) receiving blood from a subject who has been administered azathioprine or 6-mercaptopurine;
- (b) determining a level of 6-thioguanine present in said subject;
- and
- (c) indicating that a level of 6-thioguanine between about 230 pmol per 8×108 red blood cells and about 450 pmol per 8×108 red blood cells is optimal.
A method for testing 6-thioguanine levels in a subject receiving azathioprine or 6-mercaptopurine, said method comprising:
- (a) receiving blood from a subject who has been administered azathioprine or 6-mercaptopurine;
- (b) determining a level of 6-thioguanine present in said subject;
- (c) indicating that a 6-thioguanine level of less than about 230 pmol per 8×108 red blood cells is associated with lower efficacy;
- and
- (d) indicating that a 6-thioguanine level of greater than about 450 pmol per 8×108 red blood cells is associated with higher toxicity.
A method for testing 6-thioguanine levels in a subject receiving azathioprine or 6-mercaptopurine, said method comprising:
- (a) receiving blood drawn from a subject who has been administered azathioprine or 6-mercaptopurine;
- (b) using a high performance liquid chromatography machine to determine a level of 6-thioguanine present in said subject;
- (c) associating a 6-thioguanine level of less than about 230 pmol per 8×108 red blood cells with lower efficacy;
- and
- (d) associating a 6-thioguanine level of greater than about 450 pmol per 8×108 red blood cells with higher toxicity.
A method for testing 6-thioguanine levels in a subject receiving azathioprine or 6-mercaptopurine, said method comprising:
- (a) receiving blood drawn from a subject who has been administered azathioprine or 6-mercaptopurine;
- (b) determining a level of 6-thioguanine present in said subject;
- (c) associating a 6-thioguanine level of less than about 230 pmol per 8×108 red blood cells with lower efficacy;
- and
- (d) associating a 6-thioguanine level of greater than about 450 pmol per 8×108 red blood cells with higher toxicity.
Dependencies are inferred from the claim text.